Kala Pharmaceuticals (KALA) Misses Q4 EPS by 9c

Note: EPS may not be comparable

Kala Pharmaceuticals (NASDAQ: KALA) reported Q4 EPS of ($0.46), $0.09 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c